Episode 69: Summit Therapeutics

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the remarkable rise of Summit Therapeutics, a biotech that transformed itself from an infectious-disease company into one of the most closely watched oncology companies in the world. At the center of the story is ivonescimab, a next-generation bispecific antibody targeting both PD-1 and VEGF and a drug that could potentially challenge Merck’s blockbuster Keytruda. We’ll dive into Summit’s origins, the company’s dramatic p...